In this podcast, Brian and Tom engage with Pedro Barata to discuss the emerging field of bispecific T cell engagers and antibody-drug conjugates (ADCs) in the treatment of prostate cancer. They explore the promising data surrounding these therapies, the challenges faced in clinical trials, and the implications of phase three studies. The discussion also touches on the comparative development of ADCs in prostate cancer versus bladder cancer, highlighting the unique challenges and opportunities in each area. The conversation concludes with reflections on the future of these therapies and the potential for combination strategies to enhance treatment efficacy

Tom, Brian and Silke discuss the blockbuster 2025 for urothelial cancer

Silke details the 2025 prostate cancer highlights

Brian, Tom and Silke discuss the highlights of RCC for 2025

Matt Galsky joins to discuss the latest iteration of the Uromigos Score in Bladder Cancer. This score quantifies the clinical value of various approaches across several disease states. 30 global experts score each approach.

Michael Morris from MSKCC joins us for an in-depth review of ARPI development across the spectrum of prostate caner

Brian and Tom tag team moderate this session which covers combination data, VEGF/PD1 bispecifics, microbiome approaches, cellular therapy and enrichment strategies.

Tom leads the panel discussion about this evolving space including the RAMPART data and the press release about pembro/belzu.

Brian moderates a panel of Chris Sweeney, Tanya Dorff, Mike Morris, Neeraj Aggarwal and Chuck Ryan as they discus and debate the mHSPC space with many treatment options.

Brian leads a discussion of Rana McCay, Chris Sweeney and Michael Morris on the PSMAddition data and the landscape of radioligands in prostate cancer.